These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 6240996)

  • 21. Low heart and skin toxicity of a tetrahydropyranyl derivative of adriamycin (THP-ADM) as observed by electron and light microscopy.
    Dantchev D; Paintrand M; Hayat M; Bourut C; Mathé G
    J Antibiot (Tokyo); 1979 Oct; 32(10):1085-6. PubMed ID: 528374
    [No Abstract]   [Full Text] [Related]  

  • 22. Clinical phase I study of aclacinomycin A by evaluation of an intermittent intravenous administration schedule.
    Casper ES; Gralla RJ; Young CW
    Cancer Res; 1981 Jun; 41(6):2417-20. PubMed ID: 6940656
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of biotransformation in anthracycline-induced cardiotoxicity in mice.
    de Jong J; Schoofs PR; Snabilié AM; Bast A; van der Vijgh WJ
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1312-20. PubMed ID: 8371139
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Cardiotoxicity of anthracyclines].
    Laurent S; Colbert N; Izrael V; Motte G
    Ann Med Interne (Paris); 1984; 135(6):464-72. PubMed ID: 6391323
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I--II evaluation of a new anthracycline antibiotic, aclacinomycin A, in adults with refractory leukemia.
    Warrell RP; Arlin ZA; Kempin SJ; Young CW
    Cancer Treat Rep; 1982 Aug; 66(8):1619-23. PubMed ID: 6955022
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Cardiotoxic study of aclacinomycin A. Subacute cardiotoxicity of aclacinomycin A and its recovery in hamsters (author's transl)].
    Hirano S; Tone H; Sunaga T
    Jpn J Antibiot; 1980 Mar; 33(3):268-80. PubMed ID: 6931237
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effect of (2"R)-4'-O-tetrahydropyranyladriamycin, a new antitumor antibiotic, on the cardiac function of hamsters].
    Tone H; Hirano S; Shirai M; Kumagai H; Okajima Y; Wakabayashi T
    Jpn J Antibiot; 1986 Feb; 39(2):547-68. PubMed ID: 3712757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term and short-term models for studying anthracycline cardiotoxicity and protectors.
    Robert J
    Cardiovasc Toxicol; 2007; 7(2):135-9. PubMed ID: 17652818
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).
    Toma S; Tucci A; Villani G; Carteni G; Spadini N; Palumbo R
    Anticancer Res; 2000; 20(1B):485-91. PubMed ID: 10769710
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of mtDNA lesions in anthracycline cardiotoxicity.
    Lebrecht D; Walker UA
    Cardiovasc Toxicol; 2007; 7(2):108-13. PubMed ID: 17652814
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of anthracycline analogues on the appearance of newly synthesized total RNA and messenger RNA in the cytoplasm of erythroleukemia cells.
    Long BH; Willis CE; Prestayko AW; Crooke ST
    Mol Pharmacol; 1982 Jul; 22(1):152-7. PubMed ID: 6956804
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of anthracycline analogues with enhanced cytotoxicity and lack of cross-resistance to adriamycin using a series of mammalian cell lines in vitro.
    Hill BT; Dennis LY; Li XT; Whelan RD
    Cancer Chemother Pharmacol; 1985; 14(3):194-201. PubMed ID: 3858013
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative uptake of adriamycin and daunorubicin in sensitive and resistant friend leukemia cells measured by flow cytometry.
    Tapiero H; Fourcade A; Vaigot P; Farhi JJ
    Cytometry; 1982 Mar; 2(5):298-302. PubMed ID: 6951693
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Cardiotoxicity due to prolonged administration of THP (2"R-4'-O-tetrahydropyranyl-adriamycin)].
    Suzuki M; Hirono M; Majima H
    Gan To Kagaku Ryoho; 1997 Oct; 24(13):1993-9. PubMed ID: 9350248
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Administration of chromium(III) and manganese(II) as a potential protective approach against daunorubicin-induced cardiotoxicity: in vitro and in vivo experimental evidence.
    Liu Y; Wang D
    Biol Trace Elem Res; 2013 Dec; 156(1-3):253-61. PubMed ID: 24189981
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adriamycin-induced myocardial toxicity: new solutions for an old problem?
    Outomuro D; Grana DR; Azzato F; Milei J
    Int J Cardiol; 2007 Apr; 117(1):6-15. PubMed ID: 16863672
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stimulation of mouse heart and liver microsomal lipid peroxidation by anthracycline anticancer drugs: characterization and effects of reactive oxygen scavengers.
    Mimnaugh EG; Gram TE; Trush MA
    J Pharmacol Exp Ther; 1983 Sep; 226(3):806-16. PubMed ID: 6411900
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pilot studies with aclacinomycin in patients with breast cancer or gastrointestinal tumors].
    Rainer H; Gössinger H; Lenzhofer R; Moser K; Schneeweiss B
    Wien Med Wochenschr; 1983; 133(7):183-7. PubMed ID: 6868630
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Effects of 4'-Epi-adriamycin, THP-adriamycin and mitoxantrone on patients with advanced and recurrent breast cancer].
    Tominaga T; Kitamura M; Hayashi K; Takahashi I; Kosaki G
    Gan To Kagaku Ryoho; 1984 Aug; 11(8):1669-74. PubMed ID: 6591857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating, pegylated liposomes.
    Working PK; Newman MS; Sullivan T; Yarrington J
    J Pharmacol Exp Ther; 1999 May; 289(2):1128-33. PubMed ID: 10215696
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.